Doxycycline, an Inhibitor of Mitochondrial Biogenesis, Effectively Reduces Cancer Stem Cells (CSCs) in Early Breast Cancer Patients: A Clinical Pilot Study
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Doxycycline, an Inhibitor of Mitochondrial Biogenesis, Effectively Reduces Cancer Stem Cells (CSCs) in Early Breast Cancer Patients: A Clinical Pilot Study
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 8, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2018-10-12
DOI
10.3389/fonc.2018.00452
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer stem cells (CSCs): metabolic strategies for their identification and eradication
- (2018) Ernestina M. De Francesco et al. BIOCHEMICAL JOURNAL
- Bergamot natural products eradicate cancer stem cells (CSCs) by targeting mevalonate, Rho-GDI-signalling and mitochondrial metabolism
- (2018) Marco Fiorillo et al. BIOCHIMICA ET BIOPHYSICA ACTA-BIOENERGETICS
- Doxycycline targets aldehyde dehydrogenase‑positive breast cancer stem cells
- (2018) Chang‑Ching Lin et al. ONCOLOGY REPORTS
- Mitochondrial markers predict recurrence, metastasis and tamoxifen-resistance in breast cancer patients: Early detection of treatment failure with companion diagnostics
- (2017) Federica Sotgia et al. Oncotarget
- Mitochondrial mRNA transcripts predict overall survival, tumor recurrence and progression in serous ovarian cancer: Companion diagnostics for cancer therapy
- (2017) Federica Sotgia et al. Oncotarget
- Mitoketoscins: Novel mitochondrial inhibitors for targeting ketone metabolism in cancer stem cells (CSCs)
- (2017) Bela Ozsvari et al. Oncotarget
- Mitoriboscins: Mitochondrial-based therapeutics targeting cancer stem cells (CSCs), bacteria and pathogenic yeast
- (2017) Bela Ozsvari et al. Oncotarget
- NADH autofluorescence, a new metabolic biomarker for cancer stem cells: Identification of Vitamin C and CAPE as natural products targeting “stemness”
- (2017) Gloria Bonuccelli et al. Oncotarget
- Vitamin C and Doxycycline: A synthetic lethal combination therapy targeting metabolic flexibility in cancer stem cells (CSCs)
- (2017) Ernestina Marianna De Francesco et al. Oncotarget
- Repurposing of FDA-approved drugs against cancer – focus on metastasis
- (2016) Béla Ozsvári et al. Aging-US
- Bedaquiline, an FDA-approved antibiotic, inhibits mitochondrial function and potently blocks the proliferative expansion of stem-like cancer cells (CSCs)
- (2016) Marco Fiorillo et al. Aging-US
- Doxycycline inhibits the cancer stem cell phenotype and epithelial-to-mesenchymal transition in breast cancer
- (2016) Le Zhang et al. CELL CYCLE
- Cancer metabolism: a therapeutic perspective
- (2016) Ubaldo E. Martinez-Outschoorn et al. Nature Reviews Clinical Oncology
- Repurposing atovaquone: Targeting mitochondrial complex III and OXPHOS to eradicate cancer stem cells
- (2016) Marco Fiorillo et al. Oncotarget
- Therapeutic Implications of Cellular Heterogeneity and Plasticity in Breast Cancer
- (2015) Michael D. Brooks et al. Cell Stem Cell
- Doxycycline down-regulates DNA-PK and radiosensitizes tumor initiating cells: Implications for more effective radiation therapy
- (2015) Rebecca Lamb et al. Oncotarget
- Mitochondrial mass, a new metabolic biomarker for stem-like cancer cells: Understanding WNT/FGF-driven anabolic signaling
- (2015) Rebecca Lamb et al. Oncotarget
- Antibiotics that target mitochondria effectively eradicate cancer stem cells, across multiple tumor types: Treating cancer like an infectious disease
- (2015) Rebecca Lamb et al. Oncotarget
- Mitochondrial biogenesis is required for the anchorage-independent survival and propagation of stem-like cancer cells
- (2015) Arianna De Luca et al. Oncotarget
- High mitochondrial mass identifies a sub-population of stem-like cancer cells that are chemo-resistant
- (2015) Gillian Farnie et al. Oncotarget
- Mitochondria as new therapeutic targets for eradicating cancer stem cells: Quantitative proteomics and functional validation via MCT1/2 inhibition
- (2015) Rebecca Lamb et al. Oncotarget
- Long-term outcomes of first-line treatment with doxycycline in patients with previously untreated ocular adnexal marginal zone B cell lymphoma
- (2014) Jae Joon Han et al. ANNALS OF HEMATOLOGY
- Chlamydophila PsittaciEradication With Doxycycline As First-Line Targeted Therapy for Ocular Adnexae Lymphoma: Final Results of an International Phase II Trial
- (2012) Andrés J.M. Ferreri et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started